Retatrutide & Cardiometabolic Markers: TRIUMPH-1 Phase 3 Data (ADA 2026)

Why Do Researchers Study Cardiometabolic Markers Alongside Body Weight?

In metabolic receptor research, body weight is the primary pharmacological endpoint — but researchers studying the GLP-1, GIP and glucagon receptor axes have long understood that adiposity is only one aspect of what these pathways regulate. Serum lipids, blood pressure and central adiposity (measured as waist circumference) are co-regulated by the same receptor systems that govern energy balance, and studying them as secondary endpoints gives researchers a broader picture of how triple receptor agonism changes the metabolic environment in a published human trial cohort.

The rationale for each marker is grounded in receptor biology. GLP-1 receptor activation is associated with hepatic lipid metabolism and blood pressure in animal models; glucagon receptor activation has been studied for its effects on hepatic VLDL secretion and fatty acid oxidation in rodents and primates; GIP receptor signalling intersects with adipose tissue lipid flux in preclinical work. Measuring these outcomes in a large Phase 3 cohort provides a dataset that allows researchers to assess how the combination of all three receptor targets translates to systemic metabolic changes in published human pharmacology.

The TRIUMPH-1 Phase 3 trial — Eli Lilly’s pivotal study of retatrutide (LY3437943) in 2,339 adults with obesity or overweight without type 2 diabetes — pre-specified these markers as key secondary endpoints. When full data were presented at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans on 6 June 2026, they provided the most detailed cardiometabolic dataset yet published for a triple GLP-1/GIP/glucagon receptor agonist.[1] This guide summarises those reported figures in full.

What Did TRIUMPH-1 Report for Lipid Markers?

At 80 weeks on retatrutide 12 mg versus placebo, TRIUMPH-1 reported the following changes in serum lipids:[1][2]

The 41.0% triglyceride reduction is notable in the context of published GLP-1-class trials. Across earlier semaglutide Phase 3 trials, triglyceride reductions of approximately 14–20% were reported at 52–68 weeks. Tirzepatide SURMOUNT-1 reported triglyceride reductions of approximately 24% at 72 weeks. The TRIUMPH-1 figure of 41.0% at 80 weeks is substantially larger, which researchers have attributed in part to the additional contribution of glucagon receptor activation on hepatic lipid metabolism — a hypothesis that was central to the original pharmacological rationale for developing a triple agonist.[3]

Non-HDL cholesterol is a composite measure of all atherogenic lipoproteins (LDL, VLDL, IDL, Lp(a)) and is used as a secondary endpoint in metabolic trials because it captures the full atherogenic lipid burden. A 24.2% reduction in non-HDL at 80 weeks reflects widespread changes across multiple lipoprotein fractions in the published TRIUMPH-1 cohort, consistent with large shifts in hepatic lipid metabolism and adipose tissue-derived fatty acid flux.

What Did TRIUMPH-1 Report for Blood Pressure and Waist Circumference?

Alongside lipid markers, TRIUMPH-1 pre-specified systolic blood pressure and waist circumference as secondary endpoints. At 80 weeks on retatrutide 12 mg versus placebo, the trial reported:[1][2]

Waist circumference is a validated anthropometric endpoint for central adiposity and is a component of metabolic syndrome criteria. A mean reduction of 24.1 cm (approximately 9.5 inches) at 80 weeks reflects substantial redistribution of visceral adipose tissue in the published cohort. For researchers studying the relationship between receptor-mediated weight loss and adipose tissue remodelling, this magnitude of waist change — measured across a large randomised cohort — provides a dataset of interest for studying central vs. peripheral adiposity dynamics under triple receptor agonism.

The systolic blood pressure reduction of 12.3 mmHg is consistent with what is mechanistically expected from weight loss and GLP-1 receptor activation in the literature. Published models of GLP-1 receptor pharmacology in rodents have proposed both weight-dependent and weight-independent pathways for blood pressure modulation, including natriuresis and vascular effects. Whether the glucagon receptor component contributes independently to the blood pressure changes seen in TRIUMPH-1 is a question the published data cannot directly resolve, but it is an area of active mechanistic interest in receptor pharmacology research.

How Do TRIUMPH-1 and TRANSCEND-T2D-1 Cardiometabolic Data Compare?

The companion Phase 3 trial, TRANSCEND-T2D-1, studied retatrutide in adults with type 2 diabetes and was presented at the same ADA 2026 session on 6 June 2026. Its primary endpoint was at 40 weeks (vs 80 weeks for TRIUMPH-1), reflecting the different natural history in the T2D population. The cardiometabolic secondary endpoints reported were:[1]

Note: these trials differ in duration (80 vs 40 weeks), population (with vs without type 2 diabetes) and background pharmacotherapy. Direct cross-trial comparisons must be interpreted with caution and should not be used to draw mechanistic conclusions. Data shown for contextual research reference only.

The triglyceride data are notably similar across both cohorts (41.0% vs 39.6%) despite the shorter timepoint in TRANSCEND-T2D-1, suggesting a rapid effect on hepatic triglyceride metabolism that appears largely independent of diabetes status in the published cohort. The larger blood pressure and waist circumference reductions in TRIUMPH-1 likely reflect the longer follow-up duration (80 vs 40 weeks) and the greater body-weight reduction achieved in the non-diabetic obesity cohort (mean −28.3% vs −16.8% on 12 mg).

What Does TRIUMPH-1's BMI Normalization Data Show?

Beyond continuous cardiometabolic markers, TRIUMPH-1 also reported BMI normalization as a secondary endpoint — the proportion of participants who shifted from obesity or overweight into a lower BMI category. At 80 weeks on retatrutide 12 mg, the trial reported:[2][4]

• More than 65% of participants achieved a BMI below 30 kg/m² (the threshold for obesity classification)
• 33.3% achieved a BMI below 25 kg/m² (the threshold for normal BMI range)
• 45.3% achieved 30% or more body-weight reduction

For metabolic researchers, BMI normalization data is significant as a categorical endpoint. In the context of pharmacological research on triple receptor agonism, the fact that one-third of participants in a large Phase 3 cohort reached a BMI below 25 — effectively exiting the overweight range entirely — is unprecedented in published GLP-1-class trials. Prior Phase 3 datasets for semaglutide and tirzepatide did not report this proportion achieving BMI normalisation to the normal-weight range.

From a receptor pharmacology standpoint, the BMI normalization data provides researchers studying the downstream effects of combined GLP-1/GIP/glucagon receptor activation with a population-level dataset that was not previously available. Whether the glucagon receptor component contributes independently to the magnitude of adiposity reduction beyond what GLP-1 and GIP agonism alone would produce is a core scientific question that TRIUMPH-1 cannot directly resolve — but the data it provides is a reference point for future mechanistic studies.

Velox Peptides Supply Information

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions